Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of riociguat and macitentan on right ventricular function in pulmonary arterial hypertension
2015-002835-17Phase 2Completed
- Sponsor
- Justus Liebig University Giessen
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of riociguat and macitentan in pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) (2 arms), sponsored by Justus Liebig University Giessen. Primary endpoints: Change in right ventricular systolic function at 12 weeks and Change in right ventricular diastolic function at 12 weeks. Started Nov 2015; status: completed.
02
Drugs
riociguatmacitentan
03
Conditions
pulmonary arterial hypertension (PAH)pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2015-002835-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002835-17.